Calcitonin gene-related peptide (CGRP)
Calcitonin gene-related peptide (CGRP) is a neuropeptide and protein target with major relevance in pain biology, neurogenic inflammation, and migraine pathophysiology.
Calcitonin gene-related peptide (CGRP) is a neuropeptide and protein target with major relevance in pain biology, neurogenic inflammation, and migraine pathophysiology. It is widely recognized as a central mediator in migraine and can trigger attacks in susceptible individuals. In biomedical research, CGRP is often studied as part of the TRPV1/CGRP nociceptive axis and broader inflammatory signaling networks that influence sensory transmission, vascular responses, and tissue inflammation.
As a therapeutic target, CGRP has attracted substantial attention because modulation of CGRP signaling can alter headache-related and pain-related phenotypes. Recent studies also extend its relevance beyond migraine to neuropathic pain, post-stroke pain, chronic rhinosinusitis, and regenerative medicine, where CGRP is being incorporated into biomaterial systems to support immunomodulation and osteogenesis.
Where the papers sit
9 papers from the last 6 months study Calcitonin gene-related peptide (CGRP) directly · updated from PubMed 10 Oct 2026
Study type 0 clinical trials · 2 observational · 6 preclinical · 1 unclassified
Themes one subject · 2 new directions
Those 9 are all about one subject.
-
CGRP Signaling in Pain
CGRP-targeted prevention is moving beyond efficacy trials toward long-term safety assessment in migraine patients with epilepsy or prior cerebrovascular and cardiovascular disease. Mechanistic work repeatedly connects CGRP to TRPV1, NaV1.7, neuroinflammation, vascular signaling, and receptor-degradation fragments. Botulinum toxin, botanical formulations, lavender, and bergenin are being explored as indirect ways to suppress this pain network. Evidence remains preliminary for non-migraine pain and for translating these pathways into broader therapies.
CGRP is used as a sustained regenerative signal rather than primarily as a migraine or pain mediator
The femoral condyle defect study using IL-4/CGRP-loaded GelMA microspheres assumed a therapeutic role for CGRP in a controlled-release biomaterial and found that sustained CGRP release enhanced angiogenesis and osteogenic differentiation, while coordinating with immune regulation to accelerate bone formation and defect healing. This shifts CGRP into an immuno-osteogenic and tissue-regenerative role distinct from the migraine and pain mechanisms used elsewhere in the set 42093387May.
CGRP degradation products are treated as functional local signals that can alter vascular, immune, receptor, and biomarker effects
The dura mater αCGRP degradation-fragment study assumed that local CGRP availability and signaling were insufficiently explained by intact peptide levels and found that degradation fragments themselves have functional relevance at vascular, immune, and CGRP-receptor targets, with implications for biomarker detection. This gives CGRP biology a distinct role in which peptide metabolism generates biologically consequential signals rather than merely terminating CGRP action 42168858May.
Papers
The 9 papers from the last 6 months that study Calcitonin gene-related peptide (CGRP) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
CGRP Signaling in Pain (9)
- Preliminary evidence of long-term safety and effectiveness of anti-CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52-week follow-up retrospective study. Epilepsia open · 9 Oct 2026 PMID 42853599
- Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease. Journal of neurology · 15 Sept 2026 PMID 42742761
- Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. The journal of headache and pain · 11 Aug 2026 PMID 42576205
- An orexinergic circuit driving migraine relief by lavender essential oil. Current biology : CB · 9 Jul 2026 PMID 42425080
- Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program. Cephalalgia : an international journal of headache · 2 Jul 2026 PMID 42390441
- Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms. Molecular biology reports · 18 Jun 2026 PMID 42313304
- Functional characterisation of dura mater αCGRP degradation fragments at vascular, immune, and CGRP receptor targets. The journal of headache and pain · 22 May 2026 PMID 42168858
- Intranasal Da Chuanxiong formula alleviates vestibular migraine-like phenotypes via modulation of DRD2/TRPV1-associated signaling. Journal of ethnopharmacology · 17 May 2026 PMID 42144207
- Dual-function hydrogel microspheres coordinate immune regulation and osteogenesis coupling to promote femoral regeneration. Journal of materials chemistry. B · 7 May 2026 PMID 42093387
By study type
Observational studies and case reports (2)
- Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease. Journal of neurology · 15 Sept 2026 PMID 42742761
- Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program. Cephalalgia : an international journal of headache · 2 Jul 2026 PMID 42390441
Preclinical: animal, cell and lab studies (6)
- Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. The journal of headache and pain · 11 Aug 2026 PMID 42576205
- An orexinergic circuit driving migraine relief by lavender essential oil. Current biology : CB · 9 Jul 2026 PMID 42425080
- Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms. Molecular biology reports · 18 Jun 2026 PMID 42313304
- Functional characterisation of dura mater αCGRP degradation fragments at vascular, immune, and CGRP receptor targets. The journal of headache and pain · 22 May 2026 PMID 42168858
- Intranasal Da Chuanxiong formula alleviates vestibular migraine-like phenotypes via modulation of DRD2/TRPV1-associated signaling. Journal of ethnopharmacology · 17 May 2026 PMID 42144207
- Dual-function hydrogel microspheres coordinate immune regulation and osteogenesis coupling to promote femoral regeneration. Journal of materials chemistry. B · 7 May 2026 PMID 42093387
Unclassified: not yet indexed with MeSH (1)
- Preliminary evidence of long-term safety and effectiveness of anti-CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52-week follow-up retrospective study. Epilepsia open · 9 Oct 2026 PMID 42853599
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.